InterVenn Investigator Initiated Research Program in Glycoproteomics

Our Precision Medicine Product Pipeline

Indication Clinical Application Phase
Pilot Studies Classifier Validation LDT Validation Commercially Available
Ovarian Cancer Pelvic Mass Triaging
Immuno Oncology - Pancreatic, Melanoma Response Prediction / Therapy Selection
Advanced Adenoma Pre-malignant Detection, Cancer Prevention
Colorectal Cancer Early Cancer Detection, Colonoscopy Triaging
Renal Cell Carcinoma Prognosis, Clinical Management
Nasopharyngeal Carcinoma Early Detection and Clinical Decision
Interested to Learn More About our Clinical Pipeline »

The VOCALTM Trial (InterVenn test for Ovarian Cancer Liquid biopsy)

Highly accurate blood-based test for ovarian cancer diagnosis and triaging

InterVenn is developing a new benchmark-performance diagnostic test for ovarian cancer. VOCAL is a multi-site, international prospective clinical validation trial that seeks to establish whether a simple blood test can enable clinicians to distinguish with high predictive accuracy benign from malignant tumors in women presenting with a pelvic mass.

Ovarian cancer causes more deaths than any other cancer of the female reproductive system, in part because currently available tests are unreliable. Early and accurate diagnosis of ovarian cancer will improve survival, as treatment works best when cancer is detected in its early stages, and at the same time help avoid unnecessary and potentially harmful surgical intervention in patients who don’t need it.

Learn More About InterVenn's VOCALTM Trial for Ovarian Cancer »